320 related articles for article (PubMed ID: 30385821)
1. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Jones GN; Rooney C; Griffin N; Roudier M; Young LA; Garcia-Trinidad A; Hughes GD; Whiteaker JR; Wilson Z; Odedra R; Zhao L; Ivey RG; Howat WJ; Harrington EA; Barrett JC; Ramos-Montoya A; Lau A; Paulovich AG; Cadogan EB; Pierce AJ
Br J Cancer; 2018 Nov; 119(10):1233-1243. PubMed ID: 30385821
[TBL] [Abstract][Full Text] [Related]
2. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
[TBL] [Abstract][Full Text] [Related]
3. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Riches LC; Trinidad AG; Hughes G; Jones GN; Hughes AM; Thomason AG; Gavine P; Cui A; Ling S; Stott J; Clark R; Peel S; Gill P; Goodwin LM; Smith A; Pike KG; Barlaam B; Pass M; O'Connor MJ; Smith G; Cadogan EB
Mol Cancer Ther; 2020 Jan; 19(1):13-25. PubMed ID: 31534013
[TBL] [Abstract][Full Text] [Related]
5. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.
Fròsina G; Profumo A; Marubbi D; Marcello D; Ravetti JL; Daga A
Radiat Oncol; 2018 Apr; 13(1):76. PubMed ID: 29685176
[TBL] [Abstract][Full Text] [Related]
6. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
7. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
Dunlop CR; Wallez Y; Johnson TI; Bernaldo de Quirós Fernández S; Durant ST; Cadogan EB; Lau A; Richards FM; Jodrell DI
Br J Cancer; 2020 Oct; 123(9):1424-1436. PubMed ID: 32741974
[TBL] [Abstract][Full Text] [Related]
8. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
9. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
10. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
11. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
Min A; Im SA; Jang H; Kim S; Lee M; Kim DK; Yang Y; Kim HJ; Lee KH; Kim JW; Kim TY; Oh DY; Brown J; Lau A; O'Connor MJ; Bang YJ
Mol Cancer Ther; 2017 Apr; 16(4):566-577. PubMed ID: 28138034
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
13. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
[TBL] [Abstract][Full Text] [Related]
14. Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers.
Dok R; Glorieux M; Bamps M; Nuyts S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546122
[TBL] [Abstract][Full Text] [Related]
15. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
16. ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156.
Koneru B; Farooqi A; Nguyen TH; Chen WH; Hindle A; Eslinger C; Makena MR; Burrow TA; Wilson J; Smith A; Pilla Reddy V; Cadogan E; Durant ST; Reynolds CP
Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34408079
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation.
Vendetti FP; Leibowitz BJ; Barnes J; Schamus S; Kiesel BF; Abberbock S; Conrads T; Clump DA; Cadogan E; O'Connor MJ; Yu J; Beumer JH; Bakkenist CJ
Sci Rep; 2017 Feb; 7():41892. PubMed ID: 28145510
[TBL] [Abstract][Full Text] [Related]
19. ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.
Nam AR; Yoon J; Jin MH; Bang JH; Oh KS; Seo HR; Kim JM; Kim TY; Oh DY
Cancer Lett; 2021 Sep; 516():38-47. PubMed ID: 34082024
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
Foote KM; Nissink JWM; McGuire T; Turner P; Guichard S; Yates JWT; Lau A; Blades K; Heathcote D; Odedra R; Wilkinson G; Wilson Z; Wood CM; Jewsbury PJ
J Med Chem; 2018 Nov; 61(22):9889-9907. PubMed ID: 30346772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]